In the lead up to World TB Day, the Critical Path to TB Drug Regimens sponsored Cure All, a briefing on the most promising new TB drug research. Held at the Kaiser Family Foundation, the event featured a panel of senior representatives from a number of US government organizations, as well an announcement of a […]
View photos from the March 19 Cure All briefing.
Critical Path Institute (C-Path) announced that the Regulatory Science Consortium, an arm of CPTR, has added 10 new member organizations, including some of the world’s leading pharmaceuitcal developers
In advance of the 41st Union World Conference, the Global Alliance for TB Drug Development (TB Alliance) today announced the launch of the first clinical trial to test a novel tuberculosis regimen in a new development paradigm designed to speed new treatments to patients. This novel three-drug combination shows promise to treat both drug-sensitive (DS-TB) and multidrug-resistant TB (MDR-TB), and alter the course of the TB pandemic by shortening and simplifying treatment worldwide.
AstraZeneca chief executive stresses need for co-operation in tackling problem of antibiotic resistance. This week Brennan will urge ministers to work with the pharmaceutical industry to share the risks and costs in developing effective antibiotics and other treatments.
NEW TOOLS to improve the treatment and control of tuberculosis (TB) are a critical component of any comprehensive strategy to eradicate the global TB epidemic.